.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents and clinical trials in dozens of countries

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
US Army
Novartis
Boehringer Ingelheim
Chubb
Express Scripts
Dow
McKinsey
Fuji
Julphar

Generated: June 23, 2017

DrugPatentWatch Database Preview

Claims for Patent: 8,481,598

« Back to Dashboard

Claims for Patent: 8,481,598

Title:Stable dosage forms of levomilnacipran
Abstract: The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described.
Inventor(s): Surana; Rahul (Commack, NY), Divi; Murali (Ronkonkoma, NY), Chhettry; Anil (Holtsville, NY)
Assignee:
Application Number:13/006,993
Patent Claims: 1. A method for treating major depressive disorder in a patient in need thereof, comprising administering to the patient about 120 mg/day of levomilnacipran or a pharmaceutically acceptable salt thereof in one or more sustained release oral dosage forms, wherein the administering step provides a therapeutic blood plasma level of levomilnacipran or pharmaceutically acceptable salt thereof over approximately a twenty-four hour period to treat major depressive disorder in the patient, and wherein the administering step provides an average maximum plasma concentration (C.sub.max) between about 50 ng/mL and about 350 ng/mL of levomilnacipran or pharmaceutically acceptable salt thereof, an AUC.sub.0-.infin. between about 1000 nghr/mL and about 9000 nghr/mL and a T.sub.max of at least 3 hours to the patient.

2. The method of claim 1, wherein the administering step comprises administering levomilnacipran hydrochloride.

3. The method of claim 1, wherein the administering step provides a mean T.sub.max between about 4 hours and about 10 hours to the patient.

4. The method of claim 1, wherein the administering step provides a mean T.sub.max of at least 3 hours and a mean AUC.sub.0-.infin. between about 5000 nghr/mL and about 9000 nghr/mL to the patient.

5. The method of claim 1, wherein the administering step provides a mean T.sub.max of at least 3 hours and a mean AUG.sub.0-.infin. within ten percent of 5000 nghr/mL to the patient.

6. The method of claim 1, wherein the administering step provides a mean T.sub.max of at least 3 hours and a mean AUG.sub.0-.infin. within twenty percent of 5000 nghr/mL to the patient.

7. The method of claim 1, wherein the administering step further comprises administering within the sustained-release oral dosage forms between about 0.001% and about 0.5% by weight of (1S,5R) 1-phenyl-3-azabicyclo[3-1-0]hexane-2-one relative to the amount of levomilnacipran or salt thereof.

8. The method of claim 1, wherein the administering step further comprises administering within the sustained-release oral dosage forms between about 0.001% and about 0.2% by weight of (1S,5R) 1-phenyl-3-azabicyclo[3-1-0]hexane-2-one relative to the amount of levomilnacipran or salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Boehringer Ingelheim
Daiichi Sankyo
UBS
US Army
AstraZeneca
Healthtrust
McKinsey
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot